Kezar Life Sciences Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kezar Life Sciences Inc 's ROA in the first quarter of 2026?
Kezar Life Sciences Inc recorded a cumulative net loss of $-45 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -51.55%.

However, within the Healthcare sector 572 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3946, from total ROA ranking in the fourth quarter of 2025 at 4641.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-46.06 %	-47.36 %	-40.47 %	-39.35 %	-37.1 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-45	-56	-62	-71	-79
Return On Assets (TTM)	-51.55 %	-54.84 %	-51.67 %	-52.04 %	-51.15 %
KZR's Total Ranking	# 3946	# 4641	# 4036	# 4101	# 4170
Total Assets (TTM) in million	68	77	98	109	125
Seq. Total Assets Change	-11.85 %	-21.53 %	-10.49 %	-12.88 %	-13.97 %
Seq. Net Income Change	-	-	-	-	-

KZR's 5 Years Annual ROA >> Back to KZR Management Effectiveness >> Compare KZR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 250
Sector	# 573
Overall	# 3912

Return On Assets Statistics
High	Average	Low
-21.84 %	-35.5 %	-54.83 %
(Mar 31 2019)		(Dec 31 2025)

News about Kezar Life Sciences Inc Return on Assets ROA

Advancements in Autoimmune Hepatitis Treatment Kezar Life Sciences to Present Phase 2a PORTOLA Trial Data at AASLD 2025

: Kezar Life Sciences, a clinical-stage biotechnology company, is poised to present significant data from its Phase 2a PORTOLA clinical trial evaluating the efficacy of zotomipzomib in treating autoimmune hepatitis (AIH) at The Liver Meeting 2025 organized by the American Association for the Study of Liver Disease. The upcoming presentations, scheduled for November 7-11, 2025, in Washington, D.C., mark a critical step in the company s commitment to addressing unmet medical needs in immune-mediated diseases. Additionally, the company has announced a strategic 1-for-10 reverse stock split to enhance market position.Kezar Life Sciences, Inc. (Nasdaq: KZR), known for its focus on developing novel small molecule therapeutics for immune-mediated diseases, has made significant strides in the clinical evaluation of its compound zotomipzomib for the treatment of autoimmune hepatitis (AIH). Recent announcements detail the forthcoming presentation of findings from the Phase 2a PORTOLA trial at The Liver Meeting 2025, which will deliver critical insights into the potential of zotomipzomib for AIH patients.

Financial Statements
Kezar Life Sciences Inc 's Assets	$ 68 million	KZR's Balance sheet
Kezar Life Sciences Inc 's Income	$ -6 million	Quarterly KZR's Income Statement
KZR's Income by Division		See KZR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-47.02 %	-34.6 %	-26.15 %	37.46 %	43.53 %
Total Assets in million	77	145	221	300	218
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-56	-84	-102	-68	-55
Annual Return On Assets	-73.11 %	-57.88 %	-46.05 %	-22.78 %	-25.07 %

KZR's 5 Years Annual ROA >> Back to KZR Management Effectiveness >> Compare KZR ROA to its Competitors

More Return On Assets Ratios
KZR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KZR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KZR's Competitors
Subscribers only: Roa for Kezar Life Sciences Inc 's Suppliers
Subscribers only: Return On Assets for KZR's Customers

You may also want to know
KZR's Roi	KZR's Inventory Turnover Ratio	KZR's Growth Rates	KZR's Dividend Comparisons
	KZR's Profitability Ratios	KZR's Asset Turnover Ratio	KZR's Dividend Growth
KZR's Roe	KZR's Valuation Ratios	KZR's Financial Strength Ratios	KZR's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:34:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.